Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen

Published: Friday, October 05, 2012
Last Updated: Friday, October 05, 2012
Bookmark and Share
TGF-ß2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication.

Antisense Pharma GmbH has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational oncology antisense compound trabedersen to treat malignant melanoma.

Previously, trabedersen has received Orphan Drug designation by the European EMA and the US FDA in high-grade glioma (malignant brain tumor) in 2002 and in advanced pancreatic cancer in 2009.

Dr. Philippe Calais, Chief Executive Officer of Antisense Pharma comments: "We are delighted that with this most recent designation by the FDA, Trabedersen has now orphan status for three different cancer indications. With the orphan status and the associated marketing protection, we have achieved a core milestone for the long-term commercial success of our oncology lead compound trabedersen."

Dr. Hubert Heinrichs, Chief Medical Officer of Antisense Pharma elaborates: "Malignant melanoma is a very aggressive disease with a high need for innovative, effective and well-tolerated treatment options. We are confident that traberdersen will provide new hope to patients that suffer from malignant melanoma. Recently published results of our Phase I/II Study1 with traberdersen demonstrated excellent tolerability and initial encouraging survival data in patients with advanced tumors. We are currently evaluating further clinical development of traberdersen in malignant melanoma, preferably together with a potential partner."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
Trabedersen demonstrated excellent safety combined with encouraging survival in patients with advanced pancreatic cancer and malignant melanoma.
Tuesday, June 05, 2012
Antisense Pharma Internationalizes Management Board
Dr. Philippe Calais appointed Chief Executive Officer.
Tuesday, May 15, 2012
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos